Companies › Jiangsu Healthy Life Innovation Medical Technology
2 active drug programs in 14 registered trials: 8 Phase 2, 3 Phase 3, 3 Phase 1; Oncology, Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Gemcitabine hydrochloride Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 3 | Locally Advanced Pancreatic Cancer; Clear Cell Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Ovarian Brenner Tumor … | Dec 2026 |
| Tumor treating fields Electric field-based tumor treatment using alternating electric fields | – | Phase 3 | Locally Advanced Pancreatic Cancer | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02336087 | Gemcitabine hydrochloride | Phase 1 | Pancreatic Adenocarcinoma | Oncology | Dec 2026 |
| NCT05653453 | Tumor treating fields | Phase 3 | Locally Advanced Pancreatic Cancer | Oncology | Dec 2026 |
| NCT05653453 | Gemcitabine hydrochloride | Phase 3 | Locally Advanced Pancreatic Cancer | Oncology | Dec 2026 |
| NCT04233866 | Gemcitabine hydrochloride | Phase 2 | Metastatic Pancreatic Adenocarcinoma | Oncology | Dec 2026 |
| NCT01970722 | Gemcitabine hydrochloride | Phase 1 | FIGO Stage IVA Ovarian Cancer | Oncology | Jan 2027 |
| NCT02101775 | Gemcitabine hydrochloride | Phase 2 | Ovarian Brenner Tumor | Oncology | Mar 2027 |
| NCT01660971 | Gemcitabine hydrochloride | Phase 1 | Metastatic Pancreatic Adenocarcinoma | Oncology | Mar 2027 |
| NCT02595892 | Gemcitabine hydrochloride | Phase 2 | Ovarian Serous Tumor | Oncology | Aug 2027 |
| NCT06591650 | Gemcitabine hydrochloride | Phase 2 | Gallbladder Cancer Unresectable | Oncology | Oct 2027 |
| NCT07529483 | Gemcitabine hydrochloride | Phase 2 | Pancreatic Cystic Neoplasm | Oncology | Dec 2027 |
| NCT00565851 | Gemcitabine hydrochloride | Phase 3 | Clear Cell Adenocarcinoma | Oncology | Jan 2028 |
| NCT04559139 | Gemcitabine hydrochloride | Phase 2 | Stage II Gallbladder Cancer AJCC v8 | Oncology | Jul 2028 |
| NCT03609216 | Gemcitabine hydrochloride | Phase 2 | Infiltrating Bladder Urothelial Carcinoma | Oncology | Oct 2028 |
| NCT02135042 | Gemcitabine hydrochloride | Phase 2 | EBV Infection | Infectious disease | Jan 2029 |
Beijing Immunochina Medical Science & Technology Theravia InnoPharmax Jiangsu Hansoh Pharmaceutical Gilead Sciences
3D Medicines (Sichuan) PharmaEssentia Protagonist Therapeutics Greenwich LifeSciences Orca Biosystems
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.